In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Horizon Therapeutics raises $600mm through senior note sale

Executive Summary

Horizon Therapeutics PLC (formerly Horizon Pharma PLC; rare and rheumatic diseases) completed a private placement, issuing Citigroup Global Markets and other institutional buyers $600mm aggregate principal amount of 5.5% senior notes due 2027. The company will use the proceeds, as well as about $65mm of its cash on hand, to redeem or prepay $625mm of its outstanding debt (including associated premiums, fees, and accrued interest) from existing term loans and credit facilities.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies